Potential anti-tumor effects of FTY720 associated with PP2A activation: A brief review.

Potential anti-tumor effects of FTY720 associated with PP2A activation: A brief review.
Curr Med Res Opin. 2016 Mar 7;:1-19
Authors: Cristóbal I, Madoz-Gúrpide J, Manso R, González-Alonso P, Rojo F, García-Foncillas J
Abstract
FTY720 (Fingolimod, Gilenya) is an FDA-approved immunosuppressant currently used in the treatment of multiple sclerosis. However, a large number of studies over the last few years have shown that FTY720 shows potent antitumor properties that suggest its potential usefulness as a novel anticancer agent. Interestingly, the restoration of protein phosphatase 2A (PP2A) activity mediated by FTY720 could play a key role in its antitumor effects. Taking into account that PP2A inactivation is a common event that determines poor outcome in several tumor types, FTY720 could serve as an alternative therapeutic strategy for cancer patients with such alterations.
PMID: 26950691 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - March 9, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research